Ranisan 75 mg

Basic information


Ranitidine hydrochloride 84 mg in 1 coated tablet

Pharmacotherapeutic group

H2-receptor antagonists (ATC code: A02BA02)

Therapeutic indications

Short and symptomatic treatment of the signs of heartburn, gastric hyperacidity and nausea.

Pharmacological properties

Ranitidine, a histamine H2-receptor antagonist, inhibits diurnal and nocturnal gastric secretion, both basal and stimulated, thus causing a decrease in the acidity and volume of gastric juice. If administered orally, ranitidine is absorbed very rapidly and the maximum plasma level is reached within 1–3 hours. The food does not affect the biological availability of ranitidine. Biological half-life ranges between 2–3 hours, in renal insufficiency it is prolonged.

Pharmaceutical form

Film-coated tablets

More information

Posology and method of administration

One tablet is taken in case of problems; two tablets may be taken over a 24-hour period. Total duration of treatment without consulting a physician should not exceed 5 days. Tablets are taken unchewed, with or without food and with plenty of fluids.


Hypersensitivity to ranitidine or the excipients. Administer to pregnant and breast-feeding women only if clearly needed.


Ranitidine influences cytochrome P-450 so slightly, practically no drug interactions on this basis occur. By reducing the acidity of the contents of the stomach, ranitidine may reduce ketoconazole absorption. Concomitant administration of ranitidine with high doses of sucralfate (2 g) may reduce ranitidine absorption.

Undesirable effects

The following may appear: headache, dizziness, confusion in elderly people, nausea, constipation, diarrhoea, blurred vision, impotence, hair loss, allergic skin reactions, raised levels of liver enzymes, leukocytopenia and thrombocytopenia. In very rare cases, heart rhythm disorders were reported.

Special warnings and precautions for use

Before starting treatment, malignancy of the gastric ulcer must be ruled out.


The medicinal product is sold over the counter and is not covered by health insurance.

Contents of container

10 tablets

Package available in the Czech Republic

10 tablets


Detailed information

For more detailed product information, see the Summary of Product Characteristics.

Manufacturer and marketing authorisation holder

PRO.MED.CS Praha a.s., Telčská 377/1, Michle, 140 00 Prague 4, Czech Republic

Date of revision of the text

3 May 2019

Product images